PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA To evaluate the efficacy of Lanreotide Autogel 120 mg when used as primary medical treatment in untreated de novo acromegalic patients with macroadenoma, as assessed by evaluating the change in pituit...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase II, unicentre, randomized, double-blind, parallel and placebo-controlled, pilot study to evaluate the efficacy and safety of Somatuline Autogel (60 mg) in patients with active thyroid-associated ophthalmopaty of moderate intensity. Estudio piloto, de fase II, unicéntrico, aleatorizado, a doble ciego, paralelo y controlado con placebo para evaluar la eficacia y seguridad de Somatulina Autogel R (60 mg) en pacientes con oftalmopatía tiroidea activa de intensidad moderada To evaluate the efficacy and safety of 3 doses of Somatuline Autogel (60 mg) in the control of the infiltration and edema of the muscle and retrobulbar connective tissue and in the retraction and cont...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WITH DYNAMIC EQUINUS FOOT DEFORMITY DUE TO CEREBRAL PALSY The primary study objective will be to assess the efficacy of Dysport compared to placebo at Week 4 on the mean change from baseline in ankle joint hypertonicity in children with dynamic equinus foot ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

IPSEN 2-55-52030-726 : Essai de phase 3 randomisé, en double aveugle, comparant l’efficacité d’un traitement par lanreotide autogel® à un placebo chez des patients ayant une tumeur endocrine entéropancréatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multi-centre study to assess the effect of deep subcutaneous injections of lanreotide autogel 120mg adm...

• Pays France
• Organes Pancréas, Tumeurs endocrines digestives
• Spécialités Chimiothérapie

A PHASE II/III, MULTI-CENTRE, PROSPECTIVE, EXPLORATORY, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG IN THE SYMPTOMATIC TREATMENT OF PATIENTS WITH REFRACTORY DIARRHEA (MEDICAL APPROACH OF REFRACTORY DIARRHEA) The primary objective of the trial is to assess the effect of lanreotide autogel 120 mg on stool frequency in subjects with refractory diarrhea at day 28 (mean of last 7 days) compared to baseline.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Clinical research in patients with acromegaly for the assessment of test product BIM23B065, that will be given to them as repeated subcutaneous injection To assess the pharmacodynamics of repeated administration of BIM23B065 in reducing growth hormone (GH) in subjects with acromegaly

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

ENSAYO CLÍNICO DE PRUEBA DE CONCEPTO, MULTICÉNTRICO, PROSPECTIVO, ALEATORIZADO, ABIERTO Y PARALELO, PARA VALORAR LA EFICACIA DE LA BRAQUITERAPIA CON O SIN TRATAMIENTO HORMONAL CON TRIPTORELINA 22,5MG SEMESTRAL EN PACIENTES CON CÁNCER DE PRÓSTATA RECURRENTE PREVIAMENTE TRATADOS CON RADIOTERAPIA Comparar la eficacia de braquiterapia vs braquiterapia más triptorelina 22,5 mg (una inyección) semestral en pacientes con cáncer de próstata recurrente previamente tratados con radioterapia. La efica...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicentre, randomized, double-blind, parallel and controlled with placebo pilot study to evaluate the efficacy and safety of a single dose of botulinum toxin Type A (Dysport®) associated with rehabilitation treatment, in patients with primary myofascial syndrome of cervical and dorsal localization Evaluate the efficacy and safety of a single dose of botulinum toxin associated with rehabilitation treatment, on pain control in patients with primary myofascial syndrome of cervical and dorsal local...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

IPSEN 2-54-52030-156 : Essai de phase 3 randomisé, en double aveugle, comparant l’efficacité et la tolérance d’un traitement palliatif par lanréotide à un placebo chez des patients ayant un carcinomatose péritonéale. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] Phase III, multicentre, randomised, double-blind, comparative study to assess the efficacy and safety of lanreotide 30 mg versus placebo as a palliative treatment of clinical symptoms associated with ...

• Pays France
• Organes Estomac, Intestin, Secondaire du foie (métastase hépatique)
• Spécialités Chimiothérapie

Randomised, phase III multicenter, open study of lanreotide in non metastatic castration-resistant prostate cancer patients presenting elevated Chromogranin A levels To assess the efficacy in terms of Progression-free survival (PFS) of the administration of non steroidal anti androgens and LHRH-a (Arm A) versus lanreotide in addition to non steroidal anti androgen...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune